Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

928.78 +13.42 (+1.47%)
Streaming Delayed Price Updated: 12:43 PM EST, Dec 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
News headline image
Immunovant's New Candidate Provides Some Strategic Flexibility & Clarity, Analysts Say ↗
 
Via Benzinga
News headline image
Argenx Seeks FDA Nod For Its Flagship Neuromuscular Treatment Formulated For Subcutaneous Injection ↗
 
Via Benzinga
News headline image
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Argenx Gets European Marketing Authorization For Neuromuscular Disorder Candidate ↗
The European Commission (EC) has granted marketing authorization for Argenx’s (NASDAQ: ARGX) lead asset VYVGART (efgartigimod alfa-fcab) as an add-on to standard therapy for the treatment of adult... 
Via Benzinga
News headline image
Argenx's Drug Scores European Approval For Muscular Fatigue Disorder ↗
 
Via Benzinga
News headline image
Argenx's Vyvgart To 'Achieve Blockbuster Status,' This Analyst Says With 6% Price Target Hike ↗
 
Via Benzinga
News headline image
argenx: Q2 Earnings Insights ↗
  argenx (NASDAQ:ARGX) reported its Q2 earnings results on Thursday, July 28, 2022 at 01:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Recap: argenx Q2 Earnings ↗
  argenx (NASDAQ:ARGX) reported its Q2 earnings results on Thursday, July 28, 2022 at 01:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About argenx ↗
Analysts have provided the following ratings for argenx (NASDAQ:ARGX) within the last quarter: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022 ↗
  
Via Benzinga
News headline image
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
argenx announces Extraordinary General Meeting of Shareholders on September 8, 2022
From argenx SE
Via GlobeNewswire
News headline image
SVB Sees Strategic Value In This Stock As M&A Target In Autoimmune Space ↗
 
Via Benzinga
News headline image
Argenx's Vyvgart Meets Primary Goal In Late-Stage Bleeding Disorder Study ↗
 
Via Benzinga
News headline image
argenx Reports Half Year 2022 Financial Results and Provides Second Quarter Business Update
From argenx SE
Via GlobeNewswire
News headline image
Piper Sandler Maintains Overweight Rating for argenx: Here's What You Need To Know ↗
Piper Sandler has decided to maintain its Overweight rating of argenx (NASDAQ:ARGX) and raise its price target from $415.00 to $425.00. Shares of argenx are trading up 1.84% over the last 24 hours, at... 
Via Benzinga
News headline image
Golden Cross Appears Before argenx Investors ↗
If history is any guide, there may be good fortune ahead for shares of argenx (NASDAQ:ARGX). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the... 
Via Benzinga
News headline image
The Daily Biotech Pulse: AstraZeneca's 3 Product Updates, Jazz Pharma Licenses Sleeping Disorder Product, Argenx Aces Bleeding Disorder Study ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Recap: argenx Q1 Earnings ↗
argenx (NASDAQ:ARGX) reported its Q1 earnings results on Thursday, May 5, 2022 at 01:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Argenx's Vyvgart Long-Term Treatment Shows Improved gMG Disease Scores ↗
Argenx SE (NASDAQ: ARGX) announced  
Via Benzinga
News headline image
Recap: argenx Q4 Earnings ↗
argenx (NASDAQ:ARGX) reported its Q4 earnings results on Thursday, March 3, 2022 at 01:00 AM. Here's what investors need to know about the announcement. Earnings argenx... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2022 ↗
Upgrades 
Via Benzinga
News headline image
The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
argenx to Present New Data from Generalized Myasthenia Gravis Program at 2022 American Academy of Neurology Annual Meeting
From argenx SE
Via Business Wire
News headline image
The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Piper Comments On Increased Interest To Invest In Arcturus, 'Incrementally Positive' On Argenx ↗
Piper Sandler noted that Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) recently filed 10-K mentions funding of $25 million from a "pharmaceutical... 
Via Benzinga
News headline image
Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder ↗
Argenx SE (NASDAQ: ARGX) ) has  
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Pfizer Strikes COVID-19 Pill Supply Deal, Argenx Reports Positive Late-Stage Readout ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
argenx Announces Positive Topline Phase 3 Data From ADAPT-SC Study Evaluating Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
From argenx SE
Via Business Wire
News headline image
What 8 Analyst Ratings Have To Say About argenx ↗
argenx (NASDAQ:ARGX) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 4... 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.